Assembly Biosciences Inc - fluxo de caixa trimestral (NASDAQ:ASMB) | MetaTrader

Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas

Cash from operating activities -407 K-23.44 M-16.76 M-15.13 M14.24 M -41.09 M Cash from investing activities -6.7 M6.59 M16.99 M-158.27 M21.22 M -113.47 M Cash from financing activities 17 M1.92 M357 K171.93 M456 K 174.67 M Free cash flow -407 K-23.44 M-16.76 M-15.18 M14.21 M -41.16 M

Notícias

Guggenheim eleva preço-alvo da Assembly Biosciences com avanço de medicamento para herpes

Assembly Biosciences: 'Buy' On HPI Program Opt-In And HDV Candidate Development (ASMB)

Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates

Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates

Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates

Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates

GILD Exercises Option to License Assembly Bio's Herpes Programs

Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes - Assembly Biosciences (NASDAQ:ASMB), Gilead Sciences (NASDAQ:GILD)

Gilead exercises option for Assembly Bio’s herpes treatment programs

Jefferies eleva preço-alvo das ações da Assembly Biosciences para US$ 62 após dados de HSV

Jefferies raises Assembly Biosciences stock price target to $62 on HSV data

Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript